Need a safe antacid for heartburn? FDA declares Pepcid, Nexium and others free of NDMA

Zantac
Even as more drugmakers like Perrigo recall their ranitidine products because they contain NDMA, the FDA has released a list of antacid alternatives that testing has found free of the suspected carcinogen. (Sanofi)

The bad news for heartburn sufferers, of course, is that Zantac and its ranitidine generics have, perhaps for years, contained a suspected carcinogen without the FDA knowing it. The good news is that the FDA has now declared a handful of branded antacid alternatives and their generics as safe for consumers.  

The FDA Wednesday said that preliminary tests of alternatives including Pepcid (famotidine), Tagamet (cimetidine), Nexium (esomeprazole), Prevacid (lansoprazole) and Prilosec (omeprazole) found no N-nitrosodimethylamine (NDMA), the suspected cancer-causing agent found in OTC ranitidine drugs including the popular Zantac. 

RELATED: Zantac maker Sanofi joins peers in recalling antacid

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

Wednesday, July 8, 2020 | 11am EST / 8am PST

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.

The announcement came as the agency said more Zantac generic makers are voluntarily calling their meds. Dr. Reddy’s Laboratories confirmed that NDMA had been found in its ranitidine products, and Perrigo has joined the recall after testing its versions.

The recent discovery of NDMA in Zantac and its generics came after the finding last year that the impurity was being created during the manufacturing of many high blood pressure drugs like losartan and valsartan.

RELATED: Pfizer, GSK, others face negligence suits over Zantac carcinogen testing

The online pharmacy Valisure, which tests all of the products it sells, notified the FDA earlier this year that it had found a similar manufacturing phenomenon was occurring in ranitidine drugs. Valisure filed a citizen petition seeking to have the FDA have drugmakers recall the suspected products, set an acceptable NDMA level and create tests for the suspected carcinogen.

While the FDA has rejected Valisure’s testing methods, the agency has set standards and informed drugmakers how to test for NDMA in ranitidine. It announced Wednesday a new test using what it called “a more widely available technology than the first posted method.”

Suggested Articles

Johnson & Johnson will shell out at least $480 million to Emergent BioSolutions to produce millions of doses of its COVID-19 vaccine hopeful.

Despite the many HIV drugs available, some patients still can’t be successfully treated because they're drug-resistant. Now, they have a new option.

Sanofi and Regeneron have stopped their U.S. trial for Kevzara in COVID-19 after the drug showed no benefit in treating ventilated patients.